NEW YORK, August 5, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Synthetic Biologics Inc. (AMEX: SYN), OvaScience Inc. (NASDAQ: OVAS) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free research report on Keryx Biopharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=KERX. On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69 and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
Keryx Biopharmaceuticals Inc.'s stock lost 2.13%, to close the day at $7.34. The stock recorded a trading volume of 1.18 million shares, much below its three months average volume of 1.74 million shares. Over the last one month and over the past three months, Keryx Biopharmaceuticals Inc.'s shares have declined 24.17% and 28.74%, respectively. Furthermore, the stock has plummeted 48.13% since the start of this year. The company's shares are trading 23.93% below their 50-day moving average. Additionally, Keryx Biopharmaceuticals Inc. has a Relative Strength Index (RSI) of 29.31. Sign up and read the free notes on KERX at:
On Tuesday, shares in Idera Pharmaceuticals Inc. recorded a trading volume of 1.05 million shares, lower than their three months average volume of 1.71 million shares. The stock ended the day 0.57% lower at $3.49. Although, Idera Pharmaceuticals Inc.'s stock has surged 27.84% in the previous three months, it has declined 6.18% in the last one month and 20.86% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 2.25% and 5.00%, respectively. Furthermore, shares of Idera Pharmaceuticals Inc. have an RSI of 46.61. The complimentary notes on IDRA can be downloaded in PDF format at:
Synthetic Biologics Inc.'s stock lost 1.55%, to close Tuesday's session at $3.18. The stock recorded a trading volume of 1.02 million shares, much below its three months average volume of 1.74 million shares. Over the last one month and the previous three months, Synthetic Biologics Inc.'s shares have surged 16.48% and 47.22%, respectively. Additionally, the stock has rallied 117.81% since the start of this year. The company is trading 13.51% and 50.04% above its 50-day and 200-day moving averages, respectively. Furthermore, Synthetic Biologics Inc.'s stock has an RSI of 51.18. Register for free on Equity Research Institute and access the latest research on SYN at:
OvaScience Inc.'s stock finished Tuesday's session 1.59% lower at $27.88. A total of 0.40 million shares were traded, which was below its three months average volume of 0.67 million shares. Over the last one month and the previous three months, OvaScience Inc.'s shares have gained 1.27% and 13.94%, respectively. However, the stock has lost 36.95% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 11.91% and 18.57%, respectively. OvaScience Inc.'s stock has an RSI of 38.60. The complete research on OVAS is available for free at:
On Tuesday, shares in Infinity Pharmaceuticals Inc. ended the session 1.67% higher at $8.81. The stock reported a trading volume of 0.49 million shares, below its three months average volume of 0.66 million shares. Infinity Pharmaceuticals Inc.'s shares have plummeted 16.84% in the last one month, 30.10% in the previous three months and 47.81% on YTD basis. The company is trading 18.42% below its 50-day moving average and 35.93% below its 200-day moving average. Moreover, shares of Infinity Pharmaceuticals Inc. have an RSI of 32.44. Free in-depth research on INFI is available at:
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.